molecules of the year

2022

In 2022, Drug Hunter highlighted 120 Molecules of the Month with structures or stories that were published for the first time, were approved or disclosed new significant data. They were selected from tens of thousands of research articles published by leading institutions from around the world. Here is the final list of the top 10 candidates for 2022’s Molecule of the Year, nominated by our readers and reviewers. It's always incredibly hard to narrow down the group, and even harder to pick just one! These finalists are selected based on a variety of factors. There are four first-in-class compounds, the first approved de novo deuterated API, a preclinical, non-hormonal male contraceptive agent, a possible accelerated approval for the challenging-to-treat NASH, and more molecules with interesting and unique properties to choose from! You can vote and comment on your pick for the final “2022 Molecule of the Year” here.

• BMS TYK2 inhibitor
• Mirati/Array/Pfizer KRAS(G12D) inhibitor
• Madrigal THRβ-selective agonist
• GBT/Pfizer HbS polymerization inhibitor
• Myokardia/BMS cardiac myosin inhibitor
• Kura Oncology menin-MLL1 inhibitor
• LEO Pharma IL-17A modulator
• YourChoice/UMN RAR-α antagonist
• Cerevel/Pfizer M4 positive allosteric modulator
• ChemoCentryx C5aR antagonist